Recommended
Recommended
More Related Content
What's hot
What's hot (18)
Similar to Manning sherrymarketing presentation
Similar to Manning sherrymarketing presentation (20)
More from Sherry3177
Recently uploaded
Recently uploaded (20)
Manning sherrymarketing presentation
- 1. Sherry Manning Marketing Plan Inovio Pharmaceuticals
- 2. Inovio Pharmaceuticals SWOT Analysis Strengths • Ebola virus vaccine • Zika virus vaccine • TrackingT-cells in vivo Opportunities • Adding chemotherapy or other procedures to portfolio. • Connect with more collaborators. • Globalize company. Weaknesses • Research and Development. • Biopharmacies and medications. • Product pipeline Threats • Competition with more collaborators. • Limited funds and employees. • Negative perception of vaccines.
- 3. Competitive Advantage Introduction to the Ebola virusVaccine. Research and Development of the Zika virus. Years of research and development for immunotherapy and electroporation.
- 4. Strategy • Develop impressive products • Initiate more licensing agreements • Invite more experienced collaborators • Welcoming new partnerships for product pipeline • Influenza • HIV • cancer vaccines t • Retaining the staff also training and development of • Management • Technical personnel • Scientific personnel
- 5. Competition Pfizer, Inc. • Collaborating with Cellectis • Research and development • Globalized Bristol- Myers Squibb • Grants and financial support • Collaborating with Celgene Corporation • Research and development o
- 6. Strategy for Competition • Welcome new Collaborators and license agreements by commercializing through • Attending more health conferences. • Showcasing more presentations to more health research and development organizations. • Broaden the research and development to other therapies such as • Chemotherapy • Biopharmacies • Neuroscience
- 7. Target Audience • Countries. • HPV and other adult vaccines in Europe and U.S. • Universally • Hepatitis B • HIV • Influenza • Malaria
- 8. Strategy Decisions • Product • Immunotherapy • Vaccines • Electroporation • Pricing • Collaborators • Licensing Agreements • Government Funding • Distribution • Specialty Markets • Communications • Collaborators • Partners • Presentations
- 9. “ ” Marketing Implementation New Commercial Employees New Partners More Collaborators
- 10. Conclusion Inovio Pharmaceuticals is a small company that has been in business for over 30 years. They have completed many years of research and development of immunotherapies and infectious diseases. If Inovio stays with their marketing strategies and working with collaborators such as Roche then they should grow in the industry maybe become a part of Roche by merging with them. They are doing well with development of the Ebola and Zika vaccines. As long as they keep working with the government on developing vaccines for infectious diseases then that will also help them with their competitive advantage. Completed by Sherry Manning
Editor's Notes
- Has been awarded for the development the top of line immunotherapies to treat cervical dysplasia. Inovio is a prime contractor for DARPA grants for research and development of the Ebola vaccine. Preclinical testing of Zika virus has induced durable and robust immune responses. The only immunotherapy company that has reported generating T-Cells in vivo that meet the safety profile. Expand their focus on other medical procedures such as chemotherapy. Connect or reach out to more collaborators who have established themselves in the industry. Start the process of research and development for medication. Expand their business to other locations maybe globalize the company. Has a small area of focus for Research and Development. Does not include biopharmacies or medications. Is not a global company, is very small in only two areas of the U.S. Product pipeline is very small compared to their competition. Competition and the greater resources and collaborators. Limited funds and not enough qualified workers. Human vaccines are in early stages of development and competition may take it away from them. Negative perception of vaccines by the public can cause delays of product approval and sale of products.
- Inovio Pharmaceuticals competitive advantage is the fact that they are one of the first to introduce their vaccine for the Ebola virus as well as the fact that they are also researching the vaccine for the Zika virus. Both vaccines are getting positive outcomes and will help Inovio with the growth of their product pipeline and the sale of their products. Also, their key executive employees have come from a well established company's and have a lot of experience and education to bring to the table. Another good competitive advantage is that the company has been focused on immunotherapy and electroporation, which has made them very strong in that area.
- Develop impressive cancer and infectious disease products and making them available to the market by advertising and connecting with new collaborators Initiate more licensing agreements to produce and use patented technology for immunotherapy and vaccines. Welcoming new partnerships for research and development of o broaden the product pipeline. Influenza HIV cancer vaccines Retaining the management also training and development of technical personnel scientific personnel
- Pfizer, Inc. Collaborating with Cellectis to develop Chimeric Antigen Receptors for T-cells to target tumors.Research and development neuroscience, CV and metabolic diseases. Bristol-Myers Squibb Give grants and financial support to institutions researching in same areas. Collaborating with Celgene Corporation to research chemotherapy and immunnotherapy combination regimen. Research and development of biopharmacy and have spent millions on researching new drugs.
- One of Inovio Pharmaceuticals biggest competitors is Bristol-Myers Squibb. According to Bristol-Myers Squibb they have recently won the Society for Immunotherapy of Cancers Collaborators Award for ongoing collaboration and continued commitment toward the advancement of immunotherapy. Bristol-Myers Squibb has recently gone into agreement with Celgene Corporation for research and evaluate immunotherapy and chemotherapy combination regimen. Not only do they have perform research and development for immunotherapy but they are also a biopharmacy and have spent over 4 billion on research and development for new drugs. They also give grants for financial support of institutions researching in areas that Bristol- Myers Squibb has an interest in. Another Competitor is of Inovio Pharmaceuticals is Pfizer, and they also have collaborators researching immunotherapy. According to Pfizer (2016) they have recently gone into a global agreement with Cellectis to develop Chimeric Antigen Receptors for T-Cells to target tumors. Pfizer also has prescription drugs and researches in other areas such as neuroscience, CV and metabolic diseases. They are also a global company with global grants. While Inovio Pharmaceuticals does have some very strong competition their pipeline is strong. They have recently attended the American Society of Gene and Cell Therapy where they introduced the vaccine for Ebola and the turn was good because the results showed that the vaccine is safe and generated strong responses to humans. Their pipeline also includes products for HIV/AIDS, Hepatitis C and certain types of cancers. They are also in the process of research and development for vaccines for the Zika virus.
- Strive for more FDA approvals to target more hospitals and doctors outside the U.S. Expand their market by commercializing more vaccines and immunotherapies universally.
- Inovio Pharmaceuticals has a product pipeline that contains a vaccines for HPV cervical cancers. head and neck cancers, prostate cancers, They also have vaccines for lung, breast and pancreatic cancers. The infectious disease vaccines include HIV, Ebola and Influenza vaccines. Pricing Inovio receives most of it funding from the Army. Such as the US Army Medical Research Institute for Infectious Diseases. They also receive funding from US Military HIV Research Program. HIV Vaccines Trial Network, Defense Advanced Research Projects Agency. Their collaborators that pay them a large sum at the beginning of a project and usually makes payments during the period to cover overhead costs, salaries also research and development costs are companies such as Roche, Medimmune, GeneOne Life Sciences and the National Institute of Allergy and Infectious Diseases. Inovio Pharmaceuticals is relying on specialty markets for their products such as markets for infectious diseases and cancers. They are also in the process of completing a marketing plan for phase iII of their clinical trials. Inovio communicates about their products through meeting with new or prospective collaborators. They also advertise their products through word of mouth with the partners and by research and development. They are currently attending more health related conferences and presenting their portfolio and product pipeline to the health industry by attending conferences.
- To implement their marketing strategy Inovio Pharmaceuticals has brought on a new commercial executive who is responsible for marketing the portfolio of the immunotherapies and oncology. They are also hiring a new commercial director that will be responsible for marketing the treatment for HPV related cervical dysplasia in the US and Europe. They will also develop a marketing plan for the HPV franchise. The commercial director will also be working with the research and development teams to promote new products. Also, they are going to focus more on segmentation and marketing research. They are also going to implement a demand forecast to make sure there is an adequate supply of products when first put on the market and for the entire life of the product. Inovio has recently become partners with the European Organization for the Research and Treatment of Cancer. They have also collaborated with Roche who is an established company in the industry.
- To implement their marketing strategy Inovio Pharmaceuticals has brought on a new commercial executive who is responsible for marketing the portfolio of the immunotherapies and oncology. They are also hiring a new commercial director that will be responsible for marketing the treatment for HPV related cervical dysplasia in the US and Europe. They will also develop a marketing plan for the HPV franchise. The commercial director will also be working with the research and development teams to promote new products. Also, they are going to focus more on segmentation and marketing research. They are also going to implement a demand forecast to make sure there is an adequate supply of products when first put on the market and for the entire life of the product. Inovio has recently become partners with the European Organization for the Research and Treatment of Cancer. They have also collaborated with Roche who is an established company in the industry.